Identification of potential target genes associated with the effect of propranolol on angiosarcoma via microarray analysis

Zhou,Shiyong; Liu,Pengfei; Jiang,Wenhua; Zhang,Huilai

doi:10.3892/ol.2017.5968

Identification of potential target genes associated with the effect of propranolol on angiosarcoma via microarray analysis

Authors:
- Shiyong Zhou
- Pengfei Liu
- Wenhua Jiang
- Huilai Zhang
View Affiliations

Affiliations: Department of Lymphoma, Sino‑US Center of Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, P.R. China, Department of Radiotherapy, Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China
Published online on: March 31, 2017 https://doi.org/10.3892/ol.2017.5968
Pages: 4267-4275
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present study was to explore the effect of propranolol on angiosarcoma, and the potential target genes involved in the processes of proliferation and differentiation of angiosarcoma tumor cells. The mRNA expression profile (GSE42534) was downloaded from the Gene Expressed Omnibus database, including three samples without propranolol treatment (control), three samples with propranolol treatment for 4 h and three samples with propranolol treatment for 24 h. The differentially expressed genes (DEGs) in angiosarcoma tumor cells with or without propranolol treatment were obtained via the limma package of R and designated DEGs‑4 h and DEGs‑24 h. The DEGs‑24 h group was divided into two sets. Set 1 contained the DEGs also contained in the DEGs‑4 h group. Set 2 contained the remainder of the DEGs. Functional and pathway enrichment analysis of sets 1 and 2 was performed. The protein‑protein interaction (PPI) networks of sets 1 and 2 were constructed, termed PPI 1 and PPI 2, and visualized using Cytoscape software. Modules of the two PPI networks were analyzed, and their topological structures were simulated using the tYNA platform. A total of 543 and 2,025 DEGs were identified in angiosarcoma tumor cells treated with propranolol for 4 and 24 h, respectively, compared with the control group. A total of 401 DEGs were involved in DEGs‑4 h and DEGs‑24 h, including metallothionein 1, heme oxygenase 1, WW domain‑binding protein 2 and sequestosome 1. Certain significantly enriched gene ontology (GO) terms and pathways of sets 1 and 2 were identified, containing 28 overlapping GO terms. Furthermore, 121 nodes and 700 associated pairs were involved in PPI 1, whereas 1,324 nodes and 11,839 associated pairs were involved in PPI 2. A total of 45 and 593 potential target genes were obtained according to the node degrees of PPI 1 and PPI 2. The results of the present study indicated that a number of potential target genes, including AXL receptor tyrosine kinase, coatomer subunit α, DR1‑associated protein 1 and ERBB receptor feedback inhibitor 1 may be involved in the effect of propranolol on angiosarcoma.

View Figures

View References

1	Pawlik TM, Paulino AF, McGinn CJ, Baker LH, Cohen DS, Morris JS, Rees R and Sondak VK: Cutaneous angiosarcoma of the scalp: A multidisciplinary approach. Cancer. 98:1716–1726. 2003. View Article : Google Scholar : PubMed/NCBI
2	Young RJ, Brown NJ, Reed MW, Hughes D and Woll PJ: Angiosarcoma. Lancet Oncol. 11:983–991. 2010. View Article : Google Scholar : PubMed/NCBI
3	Kuntzen D, Hanel M Tufail, Kuntzen T, Yurtsever H, Tuma J, Hopfer H, Springer O and Bock A: Malignant hemangiosarcoma in a renal allograft: Diagnostic difficulties and clinical course after nephrectomy and immunostimulation. Transpl Int. 27:e70–e75. 2014. View Article : Google Scholar : PubMed/NCBI
4	Scow JS, Reynolds CA, Degnim AC, Petersen IA, Jakub JW and Boughey JC: Primary and secondary angiosarcoma of the breast: The Mayo Clinic experience. J Surg Oncol. 101:401–407. 2010.PubMed/NCBI
5	Babarović E, Zamolo G, Mustać E and Strčić M: High grade angiosarcoma arising in fibroadenoma. Diagn Pathol. 6:1252011. View Article : Google Scholar : PubMed/NCBI
6	Terada T: Angiosarcoma of the mandibular gingiva. Int J Clin Exp Pathol. 4:791–793. 2011.PubMed/NCBI
7	Sher SJ, Mujtaba MA, Yaqub MS, Taber TE, Mishler DP and Sharfuddin AA: Early fatal cutaneous lower extremity angiosarcoma associated with deep venous thrombosis in a renal transplant recipient. Exp Clin Transplant. Jul 2–2015.(Epub ahead of print). PubMed/NCBI
8	Kan T, Yanase T, Kawai M and Hide M: Angiosarcoma of elderly patients treated with weekly low-dose docetaxel in combination with radiotherapy. Skin Cancer. 28:20–23. 2013. View Article : Google Scholar
9	Stiles JM, Amaya C, Rains S, Diaz D, Pham R, Battiste J, Modiano JF, Kokta V, Boucheron LE, Mitchell DC and Bryan BA: Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma. PLoS One. 8:e600212013. View Article : Google Scholar : PubMed/NCBI
10	Albiñana V, Gómez de Las Heras K Villar, Serrano-Heras G, Segura T, Perona-Moratalla AB, Mota-Pérez M, de Campos JM and Botella LM: Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients. Orphanet J Rare Dis. 10:1182015. View Article : Google Scholar : PubMed/NCBI
11	El Hachem M, Bonamonte D, Diociaiuti A, Mantuano M and Teruzzi C: Cost-utility analysis of propranolol versus corticosteroids in the treatment of proliferating infantile hemangioma in Italy. PharmacoEconomics Italian Res Artic. 17:22015. View Article : Google Scholar
12	Diboun I, Wernisch L, Orengo CA and Koltzenburg M: Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma. BMC Genomics. 7:2522006. View Article : Google Scholar : PubMed/NCBI
13	Sherman BT, da W Huang, Tan Q, Guo Y, Bour S, Liu D, Stephens R, Baseler MW, Lane HC and Lempicki RA: DAVID Knowledgebase: A gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis. BMC Bioinformatics. 8:4262007. View Article : Google Scholar : PubMed/NCBI
14	Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, et al: STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43:D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
15	Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
16	Bandettini WP, Kellman P, Mancini C, Booker OJ, Vasu S, Leung SW, Wilson JR, Shanbhag SM, Chen MY and Arai AE: MultiContrast delayed enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: A clinical validation study. J Cardiovasc Magn Reson. 14:832012. View Article : Google Scholar : PubMed/NCBI
17	Yip KY, Yu H, Kim PM, Schultz M and Gerstein M: The tYNA platform for comparative interactomics: A web tool for managing, comparing and mining multiple networks. Bioinformatics. 22:2968–2970. 2006. View Article : Google Scholar : PubMed/NCBI
18	Gong H, Xu DP, Li YX, Cheng C, Li G and Wang XK: Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. Br J Oral Maxillofac Surg. 53:836–840. 2015. View Article : Google Scholar : PubMed/NCBI
19	Oksiuta M, Matuszczak E, Debek W, Dzienis-Koronkiewicz E and Hermanowicz A: Treatment of rapidly proliferating haemangiomas in newborns with propranolol and review of the literature. J Matern Fetal Neonatal Med. 29:64–68. 2016. View Article : Google Scholar : PubMed/NCBI
20	Praticò AD, Caraci F, Pavone P, Falsaperla R, Drago F and Ruggieri M: Propranolol: Effectiveness and failure in infantile cutaneous hemangiomas. Drug Saf Case Rep. 2:62015. View Article : Google Scholar : PubMed/NCBI
21	Sanwald R and Wagener H: Enzymes of the carbohydrate, lipid and protein metabolism in the blood vessels of the miniature pig. Z Gesamte Exp Med. 145:353–355. 1968.(In German). View Article : Google Scholar : PubMed/NCBI
22	Stroev IuI, Volgin EG, Bodrov VE and Chuchman AD: Changes in elastic and viscous properties of blood vessels in patients with diabetes mellitus and their relationship with disorders of glycoprotein and lipid metabolism. Kardiologiia. 16:130–132. 1976.(In Russian). PubMed/NCBI
23	Hassan HH, Denis M, Krimbou L, Marcil M and Genest J: Cellular cholesterol homeostasis in vascular endothelial cells. Can J Cardiol. 22 Suppl B:B35–B40. 2006. View Article : Google Scholar
24	Lee CH, Poburko D, Kuo KH, Seow CY and van Breemen C: Ca(2+) oscillations, gradients, and homeostasis in vascular smooth muscle. Am J Physiol Heart Circ Physiol. 282:H1571–H1583. 2002. View Article : Google Scholar : PubMed/NCBI
25	Ausprunk DH and Folkman J: Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res. 14:53–65. 1977. View Article : Google Scholar : PubMed/NCBI
26	Anderson M, Ober A, Mollard A, Call L, Bearss JJ, Vankayalapati H, Sharma S, Warner S and Bearss DJ: Abstract 5543: Inhibition of the tyrosine kinase receptor Axl blocks cell invasion and promotes apoptosis in pancreatic cancer cells. Cancer Res. 73:5543. 2013. View Article : Google Scholar
27	Mudduluru G and Allgayer H: The human receptor tyrosine kinase Axl gene-promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation. Biosci Rep. 28:161–176. 2008.PubMed/NCBI
28	Mudduluru G, Vajkoczy P and Allgayer H: Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer. Mol Cancer Res. 8:159–169. 2010. View Article : Google Scholar : PubMed/NCBI
29	Hafizi S and Dahlbäck B: Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev. 17:295–304. 2006. View Article : Google Scholar : PubMed/NCBI
30	Axelrod H and Pienta KJ: Axl as a mediator of cellular growth and survival. Oncotarget. 5:8818–8852. 2014. View Article : Google Scholar : PubMed/NCBI
31	Rochlitz C, Lohri A, Bacchi M, Schmidt M, Nagel S, Fopp M, Fey MF, Herrmann R and Neubauer A: Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): Results from a multicenter trial of the Swiss group for clinical cancer research (SAKK). Leukemia. 13:1352–1358. 1999. View Article : Google Scholar : PubMed/NCBI
32	Challier C, Uphoff CC, Janssen JW and Drexler HG: Differential expression of the ufo/axl oncogene in human leukemia-lymphoma cell lines. Leukemia. 10:781–787. 1996.PubMed/NCBI
33	Neubauer A, O'Bryan JP, Fiebeler A, Schmidt C, Huhn D and Liu ET: Axl, a novel receptor tyrosine kinase isolated from chronic myelogenous leukemia. Semin Hematol. 30(3 Suppl 3): S341993.
34	Tworkoski K, Singhal G, Szpakowski S, Zito CI, Bacchiocchi A, Muthusamy V, Bosenberg M, Krauthammer M, Halaban R and Stern DF: Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol Cancer Res. 9:801–812. 2011. View Article : Google Scholar : PubMed/NCBI
35	Green J, Ikram M, Vyas J, Patel N, Proby CM, Ghali L, Leigh IM, O'Toole EA and Storey A: Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours. Br J Cancer. 94:1446–1451. 2006. View Article : Google Scholar : PubMed/NCBI
36	Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM and Gilmer TM: Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL. Cancer Res. 69:6871–6878. 2009. View Article : Google Scholar : PubMed/NCBI
37	Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, Lai GM and Chuang SE: Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett. 268:314–324. 2008. View Article : Google Scholar : PubMed/NCBI